Imaging in Huntington’s Disease and Other Choreas

  • Andrew McGarryEmail author
  • Kevin M. Biglan
Part of the Current Clinical Neurology book series (CCNEU, volume 44)


Clinical and diagnostic neurology has been revolutionized by the implementation of neuroimaging in a variety of disorders. While applications for stroke, neuroimmunology, and neurooncology have been widely disseminated and become instrumental for identification and treatment of disease, imaging in neurodegenerative movement disorders has been a more challenging application. As the understanding of gradually degenerative conditions like Huntington’s disease (HD) has evolved, hypotheses regarding stages of variable dysfunction before cell death—periods of time perhaps years or decades in advance of clinical deterioration—have driven the search for biomarkers of disease. Sensitive and specific identification of biologic and anatomic changes before clinically manifest disease may offer new windows for more effective therapeutics. In this setting, newer imaging techniques have emerged as promising means to better characterize disease progression by integrating structural and functional data. We review the anatomical and functional observations made using basic and advanced imaging techniques in HD and other choreas. HD is the most prevalent choreiform disorder and most extensively evaluated via imaging, thus will be the focus of this review. Two other neurodegenerative disorders with prominent chorea, neuroacanthocytosis and Wilson’s disease, will also be discussed.


Positron Emission Tomography Single Photon Emission Compute Tomography Magnetization Transfer Imaging Raclopride Binding Total Motor Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Terrence CF, Delaney JF, Alberts MC. Computed tomography for Huntington’s disease. Neuroradiology. 1977;13(4):173–5.PubMedGoogle Scholar
  2. 2.
    Stober T, Wussow W, Schimrigk K. Bicaudate diameter—the most specific and simple CT parameter in the diagnosis of Huntington’s disease. Neuroradiology. 1984;26(1):25–8.PubMedGoogle Scholar
  3. 3.
    Sharma P, Savy L, Britton J, Taylor R, Howick A, Patton M. Huntington’s disease: a molecular genetic and CT comparison. J Neurol Neurosurg Psychiatry. 1996;60(2):206–8.PubMedGoogle Scholar
  4. 4.
    Culjkovic B, Stojkovic O, Vojvodic N, Svetel M, Rakic L, Romac S, Kostic V. Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington’s disease. J Neurol. 1999;246(11):1090–3.PubMedGoogle Scholar
  5. 5.
    Aylward EH, LI Q, Stine OC, Ranan N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA. Longitudinal change in basal ganglia volume in patients with Huntington’s disease. Neurology. 1997;48(2):394–9.PubMedGoogle Scholar
  6. 6.
    Rosas HD, Goodman J, Chen YI, Jenkins BG, Kennedy DN, Makris N, Patti M, Seidman LJ, Beal MF, Koroshetz WJ. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology. 2001;57(6):1025–8.PubMedGoogle Scholar
  7. 7.
    Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;120(Pt 12):2207–17.PubMedGoogle Scholar
  8. 8.
    Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M, Feeney J, Davis A, Rosenblatt A, Pearlson GD, Ross CA. Frontal lobe volume in patients with Huntington’s disease. Neurology. 1998;50(1):252–8.PubMedGoogle Scholar
  9. 9.
    Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage. 2000;11:805–21.PubMedGoogle Scholar
  10. 10.
    Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB. Topography of cerebral atrophy in early Huntington’s disease: a voxel-based morphometric study. J Neurol Neurosurg Psychiatry. 2004;75(2):213–20.PubMedGoogle Scholar
  11. 11.
    Kassubek J, Landwehrmeyer GB, Ecker D, Juengling FD, Muche R, Schuller S, Weindl A, Peinemann A. Global cerebral atrophy in early stages of Huntington’s disease; quantitative MRI study. Neuroreport. 2004;15(2):363–5.PubMedGoogle Scholar
  12. 12.
    Douaud G, Guara V, Ribiero MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak P, Damier P, Bachoud-Levi AC, Hantraye P, Remy P. Distribution of grey matter atrophy in Huntington disease patients: a combined ROI-based and voxel-based morphometric based study. Neuroimage. 2006;32(4):1562–75.PubMedGoogle Scholar
  13. 13.
    Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal Analysis of regional grey matter loss in Huntington’s disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry. 2008;79(2):130–5.PubMedGoogle Scholar
  14. 14.
    Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. Cerebral cortex and the clinical expression of Huntington’s disease; complexity and heterogeneity. Brain. 2008;131(Pt 4):1057–68.PubMedGoogle Scholar
  15. 15.
    Fennema-Notestine C, Archibald SL, Jacobson MW, Corey-Bloom J, Paulsen JS, Peavy GM, Gamst AC, Hamilton JM, Salmon DP, Jernigan TL. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington’s disease. Neurology. 2004;63(6):989–95.PubMedGoogle Scholar
  16. 16.
    Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB. Thalamic atrophy in Huntington’s disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex. 2005;15(6):846–53.PubMedGoogle Scholar
  17. 17.
    Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS. The distribution of structural neuropathology in preclinical Huntington’s disease. Brain. 2002;125(Pt 8):1815–28.PubMedGoogle Scholar
  18. 18.
    Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squiteri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47(2):215–22.PubMedGoogle Scholar
  19. 19.
    Jurgens CK, van de Wiel L, van Es AC, Grimbergen YM, Witjes-Ane MN, van der Grond J, Middelkoop HA, Roos RA. Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease. Neurology. 2008;255(11):1785–91.Google Scholar
  20. 20.
    Henley SM, Wild EJ, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s disease. Mov Disord. 2009;24(6):932–6.PubMedGoogle Scholar
  21. 21.
    Kloppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, Kienzle W, Tabrizi SJ, Ashburner J, Frakowiak RS, PREDICT-HD investigators of the Huntington Study Group. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology. 2009;72(5):426–31.PubMedGoogle Scholar
  22. 22.
    Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, Nance M, PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3–4):201–7.PubMedGoogle Scholar
  23. 23.
    Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D, Petersen A, Huntington Study Group PREDICT-HD Investigators. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MTI analysis. Neurobiol Dis. 2010;40(3):531–43.PubMedGoogle Scholar
  24. 24.
    Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS. Cerebral cortex structurein prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544–54.PubMedGoogle Scholar
  25. 25.
    Aylward  EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ, Magnotta VA, Juhl AR, Paulsen JS, PREDICT HD Investigators and Coordinators of the Huntington Study Group. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82(4):405–10.PubMedGoogle Scholar
  26. 26.
    Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS. Motor abnormalities in premanifest persons with Huntington’s disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763–72.PubMedGoogle Scholar
  27. 27.
    Gomez-Anson B, Alegret M, Munoz E, Monte GC, Alayrach E, Sanchez A, Boada M, Tolosa E. Prefrontal cortex volume reduction on MRI in preclinical Huntington’s disease relates to visuomotor performance and CAG number. Parkinsonism Relat Disord. 2009;15(3):213–9.PubMedGoogle Scholar
  28. 28.
    Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR. Contrasting grey and white matter changes in preclinical Huntington’s disease: an MRI study. Neurology. 2010;74(15):1208–16.PubMedGoogle Scholar
  29. 29.
    Wild EJ, Henley SM, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease. Mov Disord. 2010;25(7):888–95.PubMedGoogle Scholar
  30. 30.
    Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM. A tale of two factors: what determines the rate of progression in Huntington’s disease? A longitudinal MRI study. Mov Disord. 2011;26(9):1691–7.PubMedGoogle Scholar
  31. 31.
    Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D. Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Frost C, Langbehn DR, Reilmann R, Landwehrmeyer GB, Stout JC, TRACK-HD Investigators. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791–801.PubMedGoogle Scholar
  32. 32.
    Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31–42.PubMedGoogle Scholar
  33. 33.
    Van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA, TRACK-HD Investigator Group. Early atrophy of pallidum and accumbens nucleus in Huntington’s disease. J Neurol. 2011;258(3):412–20.PubMedGoogle Scholar
  34. 34.
    Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD Investigators. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24-month observational data. Lancet Neurol. 2012;11(1):42–53.PubMedGoogle Scholar
  35. 35.
    Jurgens CK, Bos R, Luyendijk J, Witjes-Ane MN, van der Grond J, Middelkoop HA, Roos RA. Magnetization transfer imaging in ‘premanifest’ Huntington’s disease. J Neurol. 2010;257(3):426–32.PubMedGoogle Scholar
  36. 36.
    Wolf RC, Gron G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington’s disease. J Cereb Blood Flow Metab. 2011;31(9):1908–18.PubMedGoogle Scholar
  37. 37.
    Aylward EH, Rosenblatt A, Field K, Yallapragada V, Kieburtz K, McDermott M, Raymond LA, Almqvist EW, Hayden M, Ross CA. Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study. Brain Res Bull. 2003;62(2):137–41.PubMedGoogle Scholar
  38. 38.
    Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntington’s disease. Cell Mol Biol. 2000;46(4):821–33.PubMedGoogle Scholar
  39. 39.
    Le Bhan D, Mangin JF, Poupon C, Clark C, Pappata S, Molko M, Chabriat H. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging. 2001;13:534–46.Google Scholar
  40. 40.
    Bohanna I, Georgiou-Karistianis N, Sritharan A, Asadi H, Johnston L, Churchyard A, Egan G. Diffusion tensor imaging in Huntington’s disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 2011;5(3):171–80.PubMedGoogle Scholar
  41. 41.
    Bohanna I, Georgiou-Karistianis N, Egan F. Connectivity-based segmentation of the striatum in Huntington’s disease: vulnerability of motor pathways. Neurobiol Dis. 2011;42(3):475–81.PubMedGoogle Scholar
  42. 42.
    Della Nave R, Ginestroni A, Tessa C, Giannelli M, Piacentini S, Filippi M, Mascalchi M. Regional distribution and clinical correlates of white matter structural damage in Huntington’s disease; a tract-based spatial statistics study. Am J Neuroradiol. 2010;31(9):1675–81.PubMedGoogle Scholar
  43. 43.
    Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA. Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry. 2005;76(5):650–5.PubMedGoogle Scholar
  44. 44.
    Grossman R, Yousem D. Neuroradiology: the requisites. 2nd ed. Philadelphia: Mosby; 2003.Google Scholar
  45. 45.
    Clark VP, Lai S, Deckel AW. Altered functional MRI responses in Huntington’s disease. Neuroreport. 2002;13(5):703–6.PubMedGoogle Scholar
  46. 46.
    Aron AR, Schlaghecken F, Fletcher PC, Bullmore ET, Eimer M, Barker R, Sahakian BJ, Robbins TW. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington’s disease. Brain. 2003;126(Pt 3):713–23.PubMedGoogle Scholar
  47. 47.
    Kim JS, Reading SA, Brashers-Krug T, Calhoun VD, Ross CA, Pearlson GD. Functional MRI study of a serial reaction time task in Huntington’s disease. Psychiatry Res. 2004;131(1):23–30.PubMedGoogle Scholar
  48. 48.
    Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47(2):215–22.PubMedGoogle Scholar
  49. 49.
    Wolf RC, Vasic N, Schonfelt-Lecuona C, Landwehrmeyer GB, Ecker D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington’s disease: evidence from event-related fMRI. Brain. 2007;130(Pt 11):2845–57.PubMedGoogle Scholar
  50. 50.
    RIzk-Jackson A, Stoffers D, Sheldon S, Kuperman J, Dale A, Goldstein J, Corey-Bloom J, Poldrack RA, Aron AR. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington’s disease using machine learning techniques. Neuroimage. 2011;56(2):788–96.PubMedGoogle Scholar
  51. 51.
    Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, Brooks DJ. Proton magnetic resonance spectroscopy in Huntington’s disease: evidence in favor of the glutamate excitotoxic theory. Mov Disord. 1996;11(2)167–73.PubMedGoogle Scholar
  52. 52.
    Ruocco HH, Lopes-Cendes I, LI M, Cendes F. Evidence of thalamic dysfunction in Huntington’s disease by proton magnetic resonance spectroscopy. Mov Disord. 2007;22(14):2052–6.PubMedGoogle Scholar
  53. 53.
    Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetylaspartate/choline ration and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry. 1997;62(1):27–30.PubMedGoogle Scholar
  54. 54.
    Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDOnald M, Rosen BR, Beal F, Koroshetz WJ. 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology. 1998;50(5):1357–65.PubMedGoogle Scholar
  55. 55.
    Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington’s disease. Neurology. 1999;53(4):806–12.PubMedGoogle Scholar
  56. 56.
    Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington’s disease. Brain Res. 2005;1031:(1):82–9.PubMedGoogle Scholar
  57. 57.
    Gomez-Anson B, Alegret M, Munoz E, Sainz A, Monte GC, Tolosa E. Decreased frontal choline and neuropsychological performance in preclinical Huntington’s disease. Neurology. 2007;68(12):906–10.PubMedGoogle Scholar
  58. 58.
    Van Oostrom JC, Sijens PE, Roos RA, Leenders KL. 1H magnetic resonance spectroscopoy in preclinical Huntington’s disease. Brain Res. 2007;1168:67–71.PubMedGoogle Scholar
  59. 59.
    Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington’s disease. Neurology. 2010;75(19):1702–10.PubMedGoogle Scholar
  60. 60.
    Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol. 1997;41(2):160–5.PubMedGoogle Scholar
  61. 61.
    Bender A, Auer DP, Merl T, Reilmann R, Saemann P, Yassouridis A, Bender J, Weindl A, Dose M, Gasser T, Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington’s disease. J Neurol. 2005;252(1):36–41.PubMedGoogle Scholar
  62. 62.
    Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AH, Warner TT. High-dose creatine therapy for Huntington’s disease: a two-year clinical and MRS study. Neurology. 2005;64(9):1655–6.PubMedGoogle Scholar
  63. 63.
    Schapiro M, Cecil KM, Doescher J, Kiefer AM, Jones BV. MR imaging and spectroscopy in juvenile Huntington’s disease. Pediatr Radiol. 2004;34(8):640–3.PubMedGoogle Scholar
  64. 64.
    Reynolds NC, Prost RW, Mark LP, Joseph SA. MR-spectroscopic findings in juvenile-onset Huntington’s disease. Mov Disord. 2008;23(13):1931–5.PubMedGoogle Scholar
  65. 65.
    Van den Bogaard SJ, Dumas EM, Teeuwisse WM, Kan HE, Webb A, Roos RA, van der Grond J. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington’s disease provides in vivo evidence for impaired energy metabolism. J Neurol. 2011;258(12):2230–9.PubMedGoogle Scholar
  66. 66.
    Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yebenez JG, Boesiger P, Weindl A, Maguire RP. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain. 1996;119(Pt 6):2085–95.PubMedGoogle Scholar
  67. 67.
    Antonini A, Leenders KL, Eidelberg D. [11C] raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998;43(2):253–5.PubMedGoogle Scholar
  68. 68.
    Van Oostrom JC, Dekker M, Willemsen AT, de Jong BM, Roos RA, Leenders KL. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington’s Disease. Eur J Neurol. 2009;16(2):226–31.PubMedGoogle Scholar
  69. 69.
    Ginovart N, Lundin A, Farde L, Hallidin C, Backman L, Swahn CG, Pauli S, Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain. 1997;120(Pt 3):503–14.PubMedGoogle Scholar
  70. 70.
    Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain. 1997;(Pt 12):2207–17.Google Scholar
  71. 71.
    Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ. Cortical control of movement in Huntington’s disease. A PET activation study. Brain. 1997;120(Pt 9):1569–78.PubMedGoogle Scholar
  72. 72.
    Boecker H, Ceballos-Baumann A, Bartenstein P, Weindl A, Siebner HR, Fassbender T, Munz F, Schwaiger M, Conrad B. Sensory processing in Parkinson’s and Huntington’s disease: investigations with 3D H(2)(15)O-PET. Brain. 1999;(Pt 9):1651–65.Google Scholar
  73. 73.
    Kunig G, Leenders KL, Sanchez-Pernaute R, Antonini A, Vontobel P, Verhagen A, Gunther I. Benzodiazepine receptor binding in Huntington’s disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol. 2000;47(5):644–8.PubMedGoogle Scholar
  74. 74.
    Furtado S, Sossi V, Hauser RA, Samii A, Schulzer M, Murphy CB, Freeman TB, Stoessl AJ. Positron emission tomography after fetal transplantation in Huntington’s disease. Ann Neurol. 2005;58(2):331–7.PubMedGoogle Scholar
  75. 75.
    Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, Clough C, Brooks DJ, Barker RA, Piccini P. Long term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2008;79(8):948–51.PubMedGoogle Scholar
  76. 76.
    Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P. Microglial activation correlates with severity in Huntington’s disease: a clinical and PET study. Neurolgoy. 2006;66(11):1638–43.Google Scholar
  77. 77.
    Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, Vandenberghe W. Widespread decrease of type 1 cannabinoid receptor availability in Huntington’s disease in vivo. J Nucl Med. 2010;51(9):1413–7.PubMedGoogle Scholar
  78. 78.
    Van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-vander Duin L, Pruim J, Roos RA, Leenders KL. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington’s disease. Neurology. 2005;65(6):941–3.PubMedGoogle Scholar
  79. 79.
    Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, Antonini A, Eidelberg D. Metabolic network abnormalities in early Huntington’s disease: an [(18)F] FDG PET study. J Nucl Med. 2001;42(11):1591–5.PubMedGoogle Scholar
  80. 80.
    Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington’s disease: a PET study. Brain. 2003;126(Pt 5):1127–35.PubMedGoogle Scholar
  81. 81.
    Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain. 2007;130 (Pt 11):2858–67.PubMedGoogle Scholar
  82. 82.
    Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain. 2008;131(Pt 11):2860–9.PubMedGoogle Scholar
  83. 83.
    Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA, Piccini P. Microglial activation in regions related to cognitive dysfunction predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32(2)258–70.PubMedGoogle Scholar
  84. 84.
    Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P. Cortical dopamine dysfunction in symptomatic and premanifest Huntington’s disease carriers. Neurobiol Dis. 2010;37(2):356–61.PubMedGoogle Scholar
  85. 85.
    Esmaeilzadeh M, Farde L, Karlsson P, Varrone A, Halldin C, Waters S, Tedroff J. Extrastriatal dopamine D2 receptor binding in Huntington’s disease. Hum Brain Mapp. 2011;32(10):1626–36.PubMedGoogle Scholar
  86. 86.
    Harris GJ, Aylward EH, Peyser CE, Pearlson GD, Brandt J, Roberts-Twille JV, Barta PE, Folstein SE. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington’s disease. Arch Neurol. 1996;53(4):316–24.PubMedGoogle Scholar
  87. 87.
    Sax DS, Powsner R, Kim A, Tilak S, Bhatia R, Cupples LA, Myers RH. Evidence of cortical metabolic dysfunction in early Huntington’s disease by single-photon-emission computed tomography. Mov Disord. 1996;11(6):671–7.PubMedGoogle Scholar
  88. 88.
    Leslie WD, Greenberg CR, Abrams DN, Hobson D. Clinical deficits in Huntington’s disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography. Eur J Nucl Med. 1999;26(11):1458–64.PubMedGoogle Scholar
  89. 89.
    Deckel AW, Weiner R, Szigeti D, Clark V, Vento J. Altered patterns of regional cerebral blood flow in patients with Huntington’s disease: a SPECT study during rest and cognitive or motor activation. J Nucl Med. 2000;41(5):773–80.PubMedGoogle Scholar
  90. 90.
    Gamez J, Lorenzo-Bosquet C, Cuberas-Borros G, Carmona F, Hernandez-Vara J, Castillo J, Castell-Conesa J. Does reduced [123(I)]-FP-CIT binding in Huntington’s disease suggest presynaptic dopaminergic involvement? Clin Neurol Neurosurg. 2010;112(10):870–5.PubMedGoogle Scholar
  91. 91.
    Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, Agelink M, Buttner T. Basal ganglia alterations and brain atrophy in Huntington’s disease depicted by transcranial real time sonography. J Neurol Neurosurg Psychiatry. 1999;67(4):457–62.PubMedGoogle Scholar
  92. 92.
    Deckel AW, Cohen D. Increased CBF velocity during word fluency in Huntington’s disease patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;24(2):193–206.Google Scholar
  93. 93.
    Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Elsevier; 2007.Google Scholar
  94. 94.
    Kutcher JS, Khan MJ, Andersson HC, Foundas AL. Neuroacanthocytosis masquerading as Huntington’s disease: CT/MRI findings. J Neuroimaging. 1999;9(3):187–9.PubMedGoogle Scholar
  95. 95.
    Meenakshi-Sundaram S, Arun Kumar MJ, Sridhar R, Rani U, Sundar B. Neuroacanthocytosis misdiagnosed as Huntington’s disease: a case report. J Neurol Sci. 2004;219(1–2):163–6.PubMedGoogle Scholar
  96. 96.
    Muller-Vahl KR, Berding G, Emrich HM, Peschel T. Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. J Neurol. 2007;254(8):1081–8.PubMedGoogle Scholar
  97. 97.
    Walterfang M, Looi JC, Styner M, Walker RH, Danek A, Niethammer M, Evans A, Kotschet K, Rodrigues GR, Hughes A, Velakoulis D. Shape alterations in the striatum in chorea-acanthocytosis. Psychiatry Res. 2011;192(1):29–36.PubMedGoogle Scholar
  98. 98.
    Marson AM, Bucciantini E, Gentile E, Geda C. Neuroacanthocytosis: clinical, radiological, and neurophysiological findings in an Italian family. Neurol Sci. 2003;24(3):188–9.PubMedGoogle Scholar
  99. 99.
    Nicholl DJ, Sutton I, Dotti MT, Supple SG, Danek A, Lawden M. White matter abnormalities on MRI in neuroacanthocytosis. J Neurol Neurosurg Psychiatry. 2004;75(8):1200–1.PubMedGoogle Scholar
  100. 100.
    Katsube T, Shimono T, Ashikaga R, Hosono M, Kitagaki H, Murakami T. Demonstration of cerebellar atrophy in neuroacanthocytosis of 2 siblings. Am J Neuroradiol. 2009;30(2):386–8.PubMedGoogle Scholar
  101. 101.
    Lee JH, Lee SM, Baik SK. Demonstration of striatopallidal iron deposition in chorea-acanthocytosis by susceptibility-weighted imaging. J Neurol. 2011;258(2):321–2.PubMedGoogle Scholar
  102. 102.
    Barbosa ER, Silveira-Moriyama L, Machado AC, Bachesci LA, Rosemberg S, Scaff M. Wilson’s disease with myoclonus and white matter lesions. Parkinsonism Relat Disord. 2007;13(3):185–8.PubMedGoogle Scholar
  103. 103.
    Sudmeyer M, Saleh, A, Wojtecki L, Cohnen M, Gross J, Ploner M, Hefter H, Timmerman L, Schnitzler A. Wilson’s disease tremor is associated with magnetic resonance imaging lesions in basal ganglia structures. Mov Disord. 2006;21(12):2134–9.PubMedGoogle Scholar
  104. 104.
    Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol. 1991;238(5):281–7.PubMedGoogle Scholar
  105. 105.
    De Haan J, Grossman RI, Civitello L, Hackney DB, Goldberg HI, Bilaniuk LT, Zimmerman RA. High-field magnetic resonance imaging of Wilson’s disease. J Comput Tomogr. 1987;11(2):132–5.PubMedGoogle Scholar
  106. 106.
    Hitoshi S, Iwata M, Yoshikawa K. Midbrain pathology of Wilson’s disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry. 1991;54(7):624–6.PubMedGoogle Scholar
  107. 107.
    Liebeskind DS, Wong S, Hamilton RH. Faces of the giant panda had her cub: MRI correlates in Wilson’s disease. J Neurol Neurosurg Psychiatry. 2003;74(5):682.PubMedGoogle Scholar
  108. 108.
    Jacobs DA, Markowitz CE, Liebeskind DS, Galetta SL. The “double panda” sign in Wilson’s Disease. Neurology. 2003;61(7):969.PubMedGoogle Scholar
  109. 109.
    Magalhaes AC, Caramelli P, Menezes JR, Lo LS, Bacheschi LA, Barbosa ER, Rosemberg LA, Magalhaes A. Wilson disease: MRI with clinical correlation. Neuroradiology. 1994;36(2):97–100.PubMedGoogle Scholar
  110. 110.
    Saatci I, Topcu M, Baltaoglu FF, Kose G, Yalaz K, Renda Y, Besim A. Cranial MR findings in Wilson’s disease. Acta Radiol. 1997;38(2):250–8.PubMedGoogle Scholar
  111. 111.
    Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H. Cranial MRI in Wilson’s disease. Neuroradiology. 1990;32(3):211–4.PubMedGoogle Scholar
  112. 112.
    King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, Halligan S, Hall-Craggs MA. Cranial MR imaging in Wilson’s disease. Am J Roentgenol. 1996;167(6):1579–84.Google Scholar
  113. 113.
    Sinha S, Tally AB, Ravishankar S, Prashanth LK, Venugopal KS, Arunodaya GR, Vasudev MK, Swamy HS. Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology. 2006;48(9):613–21.PubMedGoogle Scholar
  114. 114.
    Strecker K, Schneider JP, Barthel H, Hermann W, Wegner F, Wagner A, Schwartz J, Sabri O, Zimmer C. Profound midbrain atrophy in patients with Wilson’s disease and neurological symptoms? J Neuroradiol. 2006;253(8):1024–9.Google Scholar
  115. 115.
    Hedera P, Brewer GJ, Fink JK. White matter changes in Wilson disease. Arch Neurol. 2002;59(5):866–7.PubMedGoogle Scholar
  116. 116.
    van Wassenaer-van Hall HN, van den Heuvel AG, Jansen GH, Hoogenraad TU, Mali WP. Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts. Am J Neuroradiol. 1995;16(10):2021–7.PubMedGoogle Scholar
  117. 117.
    Aikath D, Gupta A, Chattopadhyay I, Hashmi MA, Gangopadhyay PK, Das SK, Ray K. Subcortical white matter abnormalities related to drug resistance in Wilson disease. Neurology. 2006;67(5):878–80.PubMedGoogle Scholar
  118. 118.
    Laranout A, Ammar N, Mourad Z, Naji S, Hentati F. Wilson’s disease: appreciable improvement of sub-cortical white matter abnormalities after copper chelating treatment: five years follow-up. Neuropediatrics. 2008;39(3):176–8.Google Scholar
  119. 119.
    Trocello JM, Guichard JP, Leyendecker A, Pernon M, Chaine P, El Balkhi S, Poupon J, Chappuis P, Woimant F. Corpus callosum abnormalities in Wilson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(10):1119–21.PubMedGoogle Scholar
  120. 120.
    Prashanth LK, Sinha S, Taly AB, Vasudev MK. Do MRI features distinguish Wilson’s disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord. 2010;25(6):672–8.PubMedGoogle Scholar
  121. 121.
    Roh JK, Lee TG, WIe BA, Lee SB, Park SH, Chang KH. Initial and follow-upbrain MRI findings and correlation with the clinical course in Wilson’s disease. Neurology. 1994;44(6):1064–8.PubMedGoogle Scholar
  122. 122.
    Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity de novo in Wilson’s disease. Neurology. 1994;44(6):1079–82.PubMedGoogle Scholar
  123. 123.
    Takahashi W, Yoshii F, Shinohara Y. Reversible magnetic resonance imaging lesions in Wilson’s disease: clinical-anatomical correlation. J Neuroimaging. 1996;6(4):246–8.PubMedGoogle Scholar
  124. 124.
    Da Costa Mdo D, Spitz M, Bacheschi LA, Leite CC, Lucato LT, Barbosa ER. Wilson’s disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI. Neuroradiology. 2009;51(10):627–33.PubMedGoogle Scholar
  125. 125.
    Huang CC, Chu NS. Wilson diseae: resolution of MRI lesions following long term oral zinc therapy. Acta Neurol Scand. 1996;93(2–3):215–8.PubMedGoogle Scholar
  126. 126.
    Cordato DJ, Fulham MJ, Yiannikas C. Pretreatment and posttreatment positron emission tomographic scan imaging in a 20-year old patient with Wilson’s disease. Mov Disord. 1998;13(1):162–6.PubMedGoogle Scholar
  127. 127.
    Wu JC, Huang CC, Jeng LB, Chu NS. Correlation of neurological manifestations and MR images in a patient with Wilson’s disease after liver transplantation. Acta Neurol Scand. 2000;102(2):135–9.PubMedGoogle Scholar
  128. 128.
    Schlaug G, Hefter H, Engelbrecht V, Kuwert T, Arnold S, Stocklin G, Seitz RJ. Neurological impairment and recovery in Wilson’s diseaes: evidence from PET and MRI. J Neurol Sci. 1996;136(1–2):129–39.PubMedGoogle Scholar
  129. 129.
    Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, Lee MC. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J Neurol Neurosurg Psychiatry. 1998;65(1):60–4.PubMedGoogle Scholar
  130. 130.
    Alanen A, Komu M, Penttinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson’s disease. Br J Radiol. 1999;72(860):749–56.PubMedGoogle Scholar
  131. 131.
    Piga M, Murru A, Serra A, Sias A, Loi G, Marrosu F, Demelia L. Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson’s disease. Eur J Nucl Med Mol Imaging. 2008;35(4):716–24.PubMedGoogle Scholar
  132. 132.
    Tarnacka B, Szeszkowski W, Buettner J, Golebiowski M, Gromadzka G, Czlonkowska A. Heterozygous carriers for Wilson disease—magnetic spectroscopy changes in the brain. Metab Brain Dis. 2009;24(3):463–8.PubMedGoogle Scholar
  133. 133.
    Tarnacka B, Szeszkowski W, Golbiowski M, Czlonkowska A. MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov Disord. 2008;23(11):1560–6.PubMedGoogle Scholar
  134. 134.
    Sener RN. Diffusion MR imaging changes associated with Wilson disease. Am J Neuroradiol. 2003;24(5):965–7.PubMedGoogle Scholar
  135. 135.
    Kawamura N, Ohyagi Y, Kawajiri M, Yoshiura T, Mihara F, Furuya H, Kira J. Serial diffusion-weighted MRI in a case of Wilson’s disease with acute onset hemichorea. J Neurol. 2004;251(11):1413–4.PubMedGoogle Scholar
  136. 136.
    Favrole P, Chabriat H, Guichard JP, Woimant F. Clinical correlates of cerebral water diffusion in Wilson’s disease. Neurology. 2006;66(3):384–9.PubMedGoogle Scholar
  137. 137.
    Sener RN. Diffusion MRI findings in Wilson’s disease. Comput Med Imaging Graph. 2003;27(1):17–21.PubMedGoogle Scholar
  138. 138.
    Walter U, Krolikowski K, Tarnacka B, Benecke R, Czlonkowska A, Dressler D. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology. 2005;64(10):1726–32.PubMedGoogle Scholar
  139. 139.
    Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H, Schneider B, Gangl A, Deecke L. Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology. 1993;43(1):120–4.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Neurology, Movement Disorders Division,Cooper University Hospital at Rowan UniversityCamdenUSA
  2. 2.Department of NeurologyUniversity of RochesterRochesterUSA

Personalised recommendations